influenza
viru
infect
uncompl
sever
life
threaten
diseas
occur
especi
young
elderli
peopl
underli
health
condit
novel
virus
emerg
influenza
virus
subtyp
circul
human
popul
sinc
respect
howev
highli
pathogen
avian
viru
emerg
china
subsequ
spread
across
europ
africa
continu
caus
sporad
zoonot
human
infect
associ
high
mortal
multipl
countri
first
pandem
centuri
caus
novel
influenza
viru
swine
origin
pandem
viru
associ
uncommonli
sever
viral
pneumonia
excess
mortal
children
young
adult
continu
circul
human
popul
today
recent
event
continu
threat
pandem
caus
subtyp
lead
renew
influenza
research
diseas
pathogenesi
clinic
manag
novel
therapeut
option
whilst
oseltamivir
antivir
treatment
appear
reduc
mortal
sever
pandem
infect
even
earli
treatment
alway
lead
surviv
therefor
treatment
option
need
investig
diseas
sever
dictat
viral
host
factor
respiratori
failur
common
caus
death
sever
case
often
caus
develop
acut
respiratori
distress
syndrom
ard
lung
patholog
postul
aris
number
factor
high
prolong
viral
replic
viral
tropism
cell
lung
differenti
activ
host
respons
particular
hypercytokinaemia
associ
sever
influenza
infect
thought
exacerb
lung
patholog
workshop
conven
bring
togeth
academ
commerci
public
sector
research
discuss
current
knowledg
field
novel
therapeut
aim
workshop
describ
mechan
lung
injuri
acut
influenza
identifi
mechan
lung
injuri
common
influenza
virus
respiratori
pathogen
identifi
potenti
immunotherapeut
target
mitig
acut
lung
injuri
review
investig
agent
develop
present
cover
observ
patholog
clinic
diseas
sever
influenza
cellular
molecular
biolog
infect
human
anim
model
novel
prototyp
intervent
therapeut
candid
includ
antagonist
commonli
prescrib
drug
immunomodulatori
properti
like
cyclooxygenas
inhibitor
statin
meet
conclud
discuss
regulatori
issu
futur
direct
studi
immunomodul
novel
therapeut
report
describ
speaker
present
commenc
overview
introduc
topic
lung
injuri
pandem
infect
professor
malik
peiri
univers
hong
kong
review
compar
diseas
spectrum
pathogenesi
avian
pandem
influenza
viru
infect
human
sinc
initi
detect
human
highli
pathogen
viru
spread
wide
endem
poultri
mani
countri
asia
africa
fuell
sporad
occurr
human
infect
high
lethal
march
total
record
case
averag
case
fatal
rate
http
sever
infect
usual
develop
otherwis
healthi
young
individu
predominantli
year
age
mild
diseas
asymptomat
infect
document
seroepidemiolog
studi
sever
ill
predomin
newli
emerg
pandem
viru
first
detect
mexico
februari
rapidli
spread
around
globe
million
peopl
infect
death
report
march
howev
underestim
total
number
death
owe
lack
ascertain
furthermor
accur
case
fatal
rate
difficult
determin
owe
incomplet
surveil
data
mild
asymptomat
case
hong
kong
seroepidemiolog
investig
hospitalis
case
allow
good
estim
pandem
infect
attack
rate
diseas
sever
overal
popul
attack
rate
found
infect
mortal
rate
highli
age
depend
whilst
overal
infect
rate
year
age
low
case
fatal
rate
increas
dramat
older
adult
ie
increas
fatal
rate
year
age
compar
children
mani
mild
asymptomat
infect
occur
especi
children
report
elsewher
thu
infect
small
number
peopl
proport
develop
sever
diseas
high
wherea
diseas
profil
pandem
infect
show
proport
sever
case
small
far
larger
proport
mild
asymptomat
infect
observ
suggest
import
role
host
genet
factor
predispos
infect
sever
diseas
pandem
virus
sever
case
occur
clinic
featur
pandem
exhibit
mani
similar
also
differ
patholog
characteris
primari
viral
pneumonia
lead
acut
respiratori
distress
syndrom
ard
multipl
organ
failur
mof
associ
lymphopenia
renal
liver
dysfunct
viru
sometim
dissemin
system
caus
extrapulmonari
diseas
major
caus
death
caus
progress
respiratori
failur
sever
pandem
diseas
associ
major
case
underli
condit
pregnanc
morbid
obes
chronic
respiratori
diseas
cardiovascular
problem
proport
sever
affect
patient
recognis
underli
condit
exceed
report
therefor
mani
previous
healthi
person
develop
sever
diseas
whilst
risk
sever
diseas
pandem
infect
lower
develop
sever
diseas
similar
lung
patholog
respiratori
complic
usual
succumb
ard
acut
respiratori
failur
contrast
sever
diseas
signific
proport
patient
sever
pandem
ill
secondari
bacteri
infect
present
fatal
case
enhanc
viral
replic
tropism
cell
lung
dysregul
inflammatori
respons
thought
contribut
lung
patholog
pandem
viral
pneumonia
evid
dysregul
host
innat
immun
respons
infect
come
clinic
observ
anim
model
infect
review
peiri
et
al
infect
induc
high
level
proinflammatori
serum
cytokin
chemokin
eg
correl
nasopharyng
viral
load
infect
macaqu
also
show
markedli
elev
level
innat
cytokin
product
correspond
prolong
viral
replic
preferenti
infect
type
ii
pneumocyt
lung
function
maintain
lung
integr
repair
compromis
influenza
infect
note
fatal
case
pandem
viru
infect
show
viral
replic
type
ii
pneumocyt
novel
attempt
reduc
diseas
sever
antagonist
use
block
innat
signal
pathway
ferret
model
ferret
infect
treat
show
reduct
weight
loss
viral
load
although
final
mortal
rate
treat
untreat
ferret
although
elev
cytokin
level
associ
enhanc
diseas
infect
pathogenesi
diseas
remain
incomplet
understood
unclear
whether
sever
diseas
ongo
viral
replic
caus
dysregul
cytokin
pattern
observ
whether
extent
cytokin
dysregul
caus
sever
diseas
correl
exist
increas
viral
load
increas
cytokin
level
continu
viral
replic
contribut
factor
diseas
one
strategi
elucid
mechan
earli
innat
respons
infect
use
vitro
system
employ
primari
human
epitheli
cell
macrophag
epitheli
cell
alveolar
macrophag
infect
viru
cytokin
produc
cell
type
act
autocrin
paracrin
manner
studi
date
shown
primari
human
macrophag
infect
differenti
express
proinflammatori
cytokin
stronger
activ
cell
signal
pathway
addit
primari
human
macrophag
infect
produc
highli
elev
level
comparison
season
infect
transcriptom
studi
macrophag
infect
season
influenza
infect
show
mark
differ
virus
quantit
rather
qualit
differ
result
activ
uniqu
signal
pathway
primari
epitheli
cell
infect
also
upregul
express
proinflammatori
cytokin
like
chemokin
cytokin
produc
epitheli
cell
macrophag
repres
start
immun
respons
paracrin
action
amplifi
broaden
host
respons
infect
progress
leucocyt
recruit
infect
site
thu
enabl
adapt
immun
develop
infect
caus
earli
rise
chemokin
expect
increas
number
immun
cell
also
recruit
lung
cyclooxygenas
found
play
central
role
amplifi
proinflammatori
respons
therefor
may
suitabl
target
therapeut
intervent
addit
recent
vitro
studi
show
endotheli
cell
also
upregul
cytokin
express
manner
similar
seen
epitheli
cell
infect
virus
infect
egress
endotheli
cell
either
apic
basolater
aspect
provid
mechan
virus
may
spread
system
upregul
cytokin
respons
virus
appear
owe
viral
polymeras
gene
whilst
degre
cytokin
induct
relat
part
polymeras
activ
viral
polymeras
protein
also
interact
host
cell
factor
involv
signal
cascad
rais
question
inform
could
use
direct
therapeut
intervent
one
area
studi
determin
whether
antivir
drug
inhibit
polymeras
activ
eg
favipiravir
could
use
antivir
immunomodul
mild
pandem
infect
viral
shed
clinic
ill
profil
appear
similar
caus
season
infect
studi
shown
protract
replic
pandem
infect
observ
histor
season
influenza
furthermor
pandem
patient
viral
pneumonia
higher
sustain
viral
load
found
tracheal
aspir
bronchoalveolar
lavag
specimen
upper
respiratori
tract
one
extent
pneumonia
seen
hospitalis
patient
pandem
ill
correl
elev
serum
cytokin
level
current
possibl
know
extent
viru
replic
lung
injuri
might
caus
cytokin
increas
experiment
infect
ferret
shown
pandem
caus
sever
diseas
season
gener
less
influenza
infect
pandem
viru
also
found
higher
titr
wide
distribut
lower
respiratori
tract
tissu
well
sometim
gastrointestin
tract
anim
model
ex
vivo
human
respiratori
tissu
cultur
compar
viral
replic
found
pandem
season
influenza
virus
greater
pandem
replic
observ
primari
bronchial
epitheli
cultur
incub
although
may
contribut
increas
virul
tracheiti
observ
human
studi
found
greater
replic
human
lung
specimen
pandem
season
virus
pandem
also
replic
human
conjunctiva
effici
season
find
reflect
subtl
differ
viral
tropism
may
play
role
pathogen
howev
unlik
viru
pandem
differ
season
viru
intrins
capabl
upregul
cytokin
alveolar
epitheli
cell
macrophag
dendrit
cell
global
gene
express
profil
infect
human
pneumocyt
similar
pandem
season
virus
although
pandem
viru
differ
season
influenza
tissu
tropism
virul
differ
subtl
host
factor
comorbid
genet
suscept
immun
would
appear
main
factor
drive
diseas
patient
sever
diseas
show
slow
viral
clearanc
prolong
hypercytokinaemia
case
current
antivir
therapi
use
alon
may
suffici
potent
antivir
regimen
eg
intraven
antivir
combin
adjunct
treatment
eg
immunomodul
passiv
immunotherapi
may
import
improv
outcom
sever
pandem
infect
dr
william
travi
columbia
univers
new
york
citi
ny
usa
describ
patholog
find
fatal
pandem
influenza
infect
adult
new
york
autopsi
report
clinic
record
histopatholog
slide
specimen
examin
describ
understand
pulmonari
patholog
relat
fatal
pandem
influenza
case
main
patholog
observ
note
pandem
fatal
includ
tracheiti
bronchiti
bronchiol
often
accompani
inflamm
ulcer
squamou
metaplasia
patholog
find
similar
observ
autopsi
pandem
instanc
lung
frequent
exhibit
oedema
haemorrhag
infiltr
lymphocyt
diffus
alveolar
damag
dad
hyalin
membran
format
hallmark
ard
type
dad
vari
patient
major
fatal
case
manifest
dad
acut
dad
case
associ
shorter
time
hospit
death
mean
day
compar
organis
dad
case
mean
day
fibros
dad
case
mean
day
pattern
similar
seen
sar
fatal
case
hospit
durat
day
less
exhibit
acut
dad
wherea
case
hospitalis
day
show
organis
dad
would
import
fulli
understand
mechan
behind
strike
pulmonari
inflammatori
reaction
patient
whilst
almost
patient
would
artifici
ventil
high
airway
pressur
oxygen
level
intervent
might
caus
addit
damag
associ
fibrosi
similar
fibrosi
also
seen
fatal
case
previou
pandem
intervent
use
therefor
thought
patholog
observ
primarili
function
diseas
rather
mechan
intervent
influenza
viru
antigen
demonstr
case
examin
commonli
tracheobronchi
tree
epithelium
also
lower
frequenc
alveolar
macrophag
alveolar
epitheli
cell
type
ii
pneumocyt
recent
macaqu
model
pandem
infect
shown
damag
type
type
ii
pneumocyt
reinforc
report
find
involv
fatal
human
case
viral
antigen
detect
nuclei
cytoplasm
alveolar
macrophag
indic
product
replic
cell
viral
antigen
often
colocalis
foci
dad
might
suggest
rapid
asynchron
kinet
viru
infect
clearanc
well
substanti
heterogen
local
pulmonari
immun
respons
rather
owe
asynchron
viral
replic
kinet
anoth
explan
could
patholog
result
inflammatori
mediat
releas
infect
area
respiratori
tract
result
direct
viru
cytopath
effect
era
pandem
characteris
high
proport
patient
develop
secondari
bacteri
infect
studi
found
fatal
pandem
case
posit
secondari
bacteri
infect
lower
report
pandem
bacteria
commonli
identifi
streptococcu
pneumonia
staphylococcu
aureu
one
case
mrsa
pandem
report
found
lower
rate
secondari
bacteri
infect
fatal
case
rang
howev
antibiot
might
administ
patient
ill
therebi
confound
bacteri
detect
upon
autopsi
uncertainti
serv
highlight
import
compil
comprehens
clinic
note
may
help
assess
usag
impact
antibiot
use
patient
pandem
influenza
studi
highlight
common
patholog
featur
seen
pandem
last
centuri
valu
autopsi
patholog
employ
modern
techniqu
eg
antemortem
ct
scan
immunohistochemistri
fix
tissu
section
seem
pulmonari
patholog
remain
consist
whilst
sector
human
popul
suscept
lethal
infect
chang
new
viral
emerg
current
pandem
death
occur
disproportion
young
adult
contrast
season
influenza
death
occur
year
age
new
york
studi
deced
includ
two
infant
adult
rang
age
year
factor
predispos
sever
viral
pneumonia
incomplet
understood
import
contribut
factor
appear
exist
underli
medic
condit
studi
fatal
comorbid
obes
bmi
patient
especi
morbid
obes
bmi
patient
disproportion
repres
exact
mechan
comorbid
contribut
sever
diseas
season
pandem
influenza
remain
fulli
understood
adiponectin
adipokin
reduc
macrophag
activ
proinflammatori
cytokin
product
produc
decreas
amount
patient
obes
decreas
postul
contribut
increas
risk
sever
influenza
addit
alter
lung
mechan
physiolog
dr
jenni
ting
univers
north
carolina
present
work
domain
protein
member
recent
discov
domain
nlr
famili
pattern
recognit
receptor
prr
prr
includ
helicas
receptor
tlr
nlr
protein
detect
cytosol
dna
via
domain
nbd
flank
region
repeat
nlr
protein
discov
date
characteris
depth
protein
adaptor
protein
pycard
protein
serv
control
product
activ
format
biochem
complex
known
inflammasom
upregul
product
activ
turn
cleav
precursor
function
form
nlr
protein
naip
also
abl
activ
produc
function
mutat
found
popul
caus
rare
inflammatori
diseas
known
period
syndrom
cap
treatment
use
antagonist
found
success
amelior
diseas
inflammasom
involv
innat
respons
wide
varieti
bacteri
fungal
viral
stimuli
includ
influenza
viru
mous
knockout
model
viru
infect
found
necessari
viral
clearanc
surviv
even
though
infect
mice
less
pulmonari
patholog
thu
increas
pulmonari
cellular
infiltr
observ
model
appear
necessari
protect
diseas
death
similar
experi
show
pycard
also
necessari
protect
influenza
mice
also
fail
mount
detect
serum
serum
pulmonari
pulmonari
respons
whilst
nlr
protein
link
ifn
product
effect
type
ifn
respons
seen
mous
model
well
respond
pathogen
stimuli
also
respond
stimuli
known
damp
molecular
pattern
damp
compris
endogen
cellular
extracellular
molecul
releas
upon
stress
damag
includ
chemic
silica
crystal
alum
salt
damp
undergo
lysosom
degrad
caus
releas
lysosom
cathepsin
b
associ
activ
subsequ
product
cell
death
lysosom
degrad
product
also
initi
format
reactiv
oxygen
speci
ro
cytosol
turn
also
activ
vitro
vivo
mous
experi
show
ro
inhibit
reduc
respons
influenza
infect
suggest
ro
format
necessari
inflammasom
activ
influenza
infect
cathepsin
b
also
found
necessari
influenza
respons
result
indic
inflammasom
respons
influenza
infect
involv
lysosom
cathepsin
b
ro
typic
damp
detect
pathway
howev
discuss
ro
also
contribut
lung
damag
inhibitor
like
cystein
use
individu
case
sever
pandem
influenza
addit
viral
rna
sens
also
found
import
initi
inflammasom
respons
mice
expos
synthet
rna
analogu
dsrna
ssrna
subsequ
mediat
inflammasom
product
observ
potenti
inform
therapeut
choic
futur
studi
although
much
work
necessari
characteris
magnitud
time
cytokin
respons
influenza
virus
model
involv
speci
determin
particular
immunomodul
might
benefit
retard
viral
clearanc
dr
david
topham
univers
rochest
present
data
describ
adapt
immun
respons
mous
influenza
model
clearanc
viral
infect
epitheli
cell
larg
mediat
cytotox
cell
primari
influenza
infect
mice
cytotox
cell
recruit
respiratori
tract
peak
day
sever
day
peak
viral
titr
secondari
infect
acceler
cell
respons
viru
clearanc
occur
earlier
human
infect
older
children
adult
influenza
almost
alway
secondari
infect
peopl
expos
influenza
earli
life
secondari
immun
respons
involv
recruit
memori
cell
mucos
lymphoid
tissu
eg
lymphoid
tissu
nalt
circul
memori
pool
extrapulmonari
lymphoid
tissu
memori
cell
tend
exhibit
phenotyp
enabl
firstli
migrat
respiratori
tract
upon
secondari
challeng
secondli
appropri
effector
function
integrin
express
resid
lung
cell
upregul
cell
influenza
infect
mous
knockout
model
develop
tissu
memori
cell
found
impair
influenza
infect
therebi
establish
role
lung
memori
gener
cell
found
day
lung
airway
mice
fewer
lung
cell
express
less
lung
cell
contrast
cell
express
howev
primari
infect
mice
express
cell
increas
therebi
produc
uniqu
subset
memori
cell
resid
lung
cell
distinguish
central
counterpart
memori
cell
appear
primari
effector
cell
secondari
viru
challeng
cell
reactiv
within
hour
secondari
infect
account
major
earli
cytokin
product
mous
lung
contrast
typic
effector
memori
cell
lymphoid
tissu
prolifer
popul
day
migrat
lung
tissu
day
data
consist
distinct
lymphoid
subset
sequenti
activ
secondari
infect
model
homeostat
cytokin
produc
nk
cell
stimul
epitheli
prolifer
defici
leav
anim
suscept
lethal
lung
gut
infect
use
microarray
gene
express
chip
increas
detect
secondari
influenza
infect
mous
concurr
decreas
express
turn
may
impact
nk
cell
product
lung
nk
cell
product
depend
level
lung
decreas
day
primari
infect
mice
treat
antibodi
display
limit
weight
loss
mortal
note
lung
viral
titr
reduc
mice
togeth
suggest
may
activ
regul
influenza
infect
limit
epitheli
prolifer
effect
decreas
target
cell
number
dr
megan
shaw
mount
sinai
school
medicin
new
york
ny
usa
review
recent
work
determin
human
cellular
factor
requir
influenza
replic
limit
code
capac
influenza
viru
mean
must
hijack
number
host
cellular
factor
complet
replic
cycl
knowledg
interact
offer
opportun
design
novel
therapeut
disrupt
prevent
interact
limit
viru
replic
one
approach
involv
use
short
interf
rna
sirna
screen
method
elucid
host
factor
necessari
influenza
replic
briefli
method
entail
transfect
human
epitheli
cell
line
sirna
cover
approxim
gene
follow
infect
recombin
wsn
viru
code
region
haemagglutinin
gene
replac
renilla
luciferas
gene
amongst
host
gene
affect
viru
replic
without
sirna
directli
confer
cell
toxic
fell
function
group
includ
kinas
regul
signal
ubiquitin
pathway
phosphatas
activ
transcript
factor
integr
protein
interact
data
avail
databas
dens
interact
network
contain
confirm
host
protein
influenza
viru
protein
form
within
network
cellular
pathway
previous
implic
influenza
viru
replic
well
novel
host
pathway
complex
coat
protein
copi
complex
fibroblast
growth
factor
receptor
fgfr
signal
pathway
note
work
detect
elev
earli
viral
replic
may
identifi
antivir
host
factor
limit
screen
method
utilis
could
assess
effect
sirna
multicycl
replic
owe
lack
ha
code
region
recombin
viru
use
infect
screen
host
factor
identifi
affect
viral
replic
confirm
necessari
viru
growth
multicycl
growth
assay
one
factor
export
protein
nucleu
knockdown
experi
found
necessari
viral
entri
requir
nuclear
import
viral
rnp
twelv
repres
host
factor
shown
necessari
wsn
replic
well
pandem
viru
replic
indic
host
factor
identifi
paper
like
applic
influenza
virus
four
studi
use
rnai
screen
technolog
influenza
infect
publish
recent
perhap
surprisingli
appear
modest
overlap
host
factor
identifi
studi
konig
et
al
karla
et
al
share
highest
number
match
host
factor
perhap
studi
use
epitheli
cell
line
viru
strain
experi
studi
use
differ
virus
ie
envelop
viru
differ
cell
line
eg
hbec
drosophila
cell
line
sourc
rnai
librari
may
also
contribut
factor
observ
variat
howev
analys
carri
pathway
complex
level
rather
gene
level
common
pathway
identifi
across
publish
studi
influenza
includ
pathway
involv
ion
transport
nuclear
pore
function
kinas
signal
addit
analys
extend
identifi
host
pathway
share
influenza
rna
virus
eg
hiv
hcv
mani
common
cellular
pathway
complex
found
exampl
certain
share
kinas
signal
complex
necessari
influenza
hiv
hcv
wnv
replic
final
host
inhibitor
influenza
replic
test
exampl
host
cell
kinas
involv
cytoskelet
regul
transcript
found
need
optim
influenza
viru
polymeras
activ
postul
involv
viral
rna
transcript
use
inhibitor
viral
replic
reduc
manner
vitro
diphyllin
inhibit
vatpas
sever
member
identifi
screen
also
effect
reduc
viral
replic
inhibitor
warrant
studi
anim
model
influenza
studi
shown
host
inhibitor
like
target
rafmekerk
kinas
pathway
activ
lead
decreas
viral
replic
dr
robert
mason
nation
jewish
health
centr
denver
co
usa
describ
express
innat
immun
gene
alveolar
epitheli
cell
macrophag
influenza
infect
vitro
method
cultur
differenti
type
ii
pneumocyt
alveolar
macrophag
primari
human
cell
previous
establish
type
ii
pneumocyt
predominantli
express
sialic
acid
receptor
make
preferenti
permiss
avian
viral
subtyp
infect
rather
human
season
influenza
virus
cultur
type
ii
pneumocyt
alveolar
macrophag
infect
viru
reassort
viru
ha
na
np
gene
remain
gene
virus
abl
infect
cell
type
pneumocyt
abl
support
product
viru
replic
host
innat
immun
respons
determin
mrna
express
use
affymetrix
gene
chip
follow
verif
elisa
experi
concentr
first
hour
time
cytopath
effect
observ
type
ii
pneumocyt
display
mark
increas
express
cytokin
chemokin
prr
molecul
infect
particular
includ
ifn
respons
gene
rant
unexpectedli
group
chemokin
found
substanti
upregul
two
virus
induc
cytokin
type
overal
viru
elicit
lower
level
compar
particular
induc
markedli
increas
level
compar
infect
reason
differ
unclear
virus
exhibit
similar
replic
level
system
observ
highlight
import
differ
host
respons
amongst
differ
influenza
virus
viral
infect
alveolar
macrophag
cultur
mainli
elicit
similar
innat
respons
seen
type
ii
pneumocyt
cell
although
infect
macrophag
produc
lower
level
lung
surfact
suppress
enhanc
inflammatori
signal
rest
lung
surfact
help
downregul
inflamm
via
wherea
damag
lung
surfact
allow
activ
human
also
shown
inhibit
influenza
infect
alveolar
macrophag
activ
vitro
infect
cultur
type
ii
pneumocyt
consist
chang
express
detect
experi
would
expect
suppress
infect
therefor
slow
cytopath
effect
especi
circul
virus
highli
glycosyl
ha
known
inhibit
greater
extent
virus
ha
surfac
protein
less
glycosyl
recent
pandem
viru
origin
hypercytokinaemia
associ
sever
influenza
diseas
may
due
cytokin
produc
cell
initi
infect
cytokin
produc
neighbour
cell
paracrin
action
work
carri
rat
lung
epitheli
cell
infect
coronaviru
show
cell
express
cxc
chemokin
express
viral
protein
indic
system
cxc
chemokin
express
result
paracrin
effect
addit
antagonist
solubl
tnfr
abl
block
cxc
chemokin
secret
rat
coronaviru
sialodacryoaden
viru
sdav
alveolar
epitheli
cell
partli
respons
cxc
chemokin
product
influenza
infect
alveolar
macrophag
addit
antagonist
solubl
tnfr
abl
reduc
secret
approxim
much
observ
addit
inactiv
viru
observ
demonstr
alveolar
type
ii
pneumocyt
abl
respond
robustli
influenza
viru
strain
respiratori
virus
play
signific
role
initi
innat
immun
respons
elabor
proinflammatori
cytokin
respons
might
especi
import
pathogenesi
sever
influenza
viral
pneumonia
professor
yumiko
imai
akita
univers
school
medicin
japan
present
data
elucid
mechan
innat
immun
signal
pathogenesi
ard
novel
intervent
therapi
tlr
previous
observ
play
role
increas
lung
injuri
exampl
mous
model
ard
use
understand
innat
immun
mechan
found
mice
exhibit
natur
resist
lung
injuri
tlr
act
pathogen
recognit
receptor
varieti
extracellular
intracellular
pathogen
commonli
associ
extracellular
bacteri
lipopolysaccharid
lp
recognit
interestingli
also
involv
rsv
inflammatori
respons
infect
influenza
viru
mice
show
increas
tlr
gene
express
lung
tissu
signal
pathway
involv
either
trif
activ
lead
activ
final
transcript
proinflammatori
cytokin
associ
respons
associ
sever
influenza
diseas
examin
role
respons
influenza
mice
inocul
inactiv
viru
use
immunohistochemistri
viral
antigen
observ
lung
pneumocyt
commonli
alveolar
macrophag
viru
inocul
mice
show
much
reduc
level
sever
diseas
characteris
reduc
lung
elast
pulmonari
inflamm
mice
exhibit
similar
reduct
lung
injuri
indic
lung
injuri
caus
pathway
murin
model
sever
lung
injuri
correl
increas
product
variou
proinflammatori
cytokin
chemokin
ie
kc
accord
previou
observ
season
elicit
lower
proinflammatori
cytokin
alveolar
macrophag
similar
respons
seen
inactiv
season
influenza
viru
administr
find
underscor
import
viral
virul
factor
oxid
stress
previous
link
inflammatori
respons
ali
influenza
virus
express
ha
show
increas
reactiv
oxygen
speci
ro
express
lung
infect
mice
oxid
stress
also
seen
recruit
lipid
raft
plasma
membran
alveolar
macrophag
oxidis
phospholipid
oxpapc
gener
site
inflamm
furthermor
oxpapc
found
membran
apoptot
macrophag
atherosclerosi
mediat
inflammatori
effect
properti
oxpapc
also
report
sepsi
ali
propos
act
direct
antagon
lp
recognit
base
prior
observ
one
hypothesi
caus
product
ro
convert
pl
oxpl
therebi
trigger
pathway
inde
upregul
ro
membran
recruit
alveolar
macrophag
observ
mice
given
inactiv
inactiv
season
viru
oxidis
pl
also
found
lung
inactiv
live
mice
oxpapc
enhanc
express
pathway
demonstr
studi
administ
oxpapc
mice
contribut
ro
oxpl
format
ali
assess
diminish
ro
product
mice
mutat
ncf
nadph
oxidas
gene
mice
show
less
lung
diseas
upon
inactiv
viru
inocul
viru
infect
human
immunohistochem
stain
lung
specimen
show
posit
stain
oxpl
collabor
john
nichol
malik
peiri
univers
hong
kong
summari
viru
appear
induc
format
ro
oxidis
papc
oxpapc
abl
trigger
lead
signal
pathway
enabl
activ
proinflammatori
cytokin
respons
particularli
contribut
ali
interestingli
underli
risk
factor
sever
diseas
influenza
also
associ
increas
oxid
stress
rais
ro
level
exampl
obes
diabet
sar
outbreak
saw
patient
sar
develop
ard
sar
viru
studi
reveal
potenti
therapeut
ard
cellular
receptor
sar
enzym
compon
system
ra
review
kuba
et
al
serv
neg
regul
wherea
ace
anoth
compon
ra
exacerb
diseas
outcom
ace
polymorph
human
popul
found
significantli
associ
increas
mortal
patient
ard
sar
infect
sar
coronaviru
spike
protein
administr
mice
downregul
sar
receptor
exacerb
ard
contrast
knockout
mice
protect
product
sar
viru
infect
comparison
mice
knockout
mice
shown
sever
impair
lung
function
increas
lung
oedema
ard
caus
acid
aspir
sepsi
novel
recombin
human
treatment
shown
protect
acut
lung
injuri
ard
mous
model
preliminari
studi
therapi
experiment
influenza
infect
current
carri
mice
observ
offer
novel
ration
drug
strategi
treatment
ard
ali
caus
influenza
respiratori
virus
extrapulmonari
trigger
ard
includ
antagonist
host
innat
immun
respons
trif
intervent
oxid
stress
machineri
modif
lipid
metabol
pathway
eg
statin
inhibitor
intervent
ra
ace
antagonist
therapi
dr
erika
wisseng
imperi
colleg
london
present
data
professor
traci
hussel
group
regard
mucos
innat
immun
mucos
site
continu
expos
predominantli
innocu
stimuli
therefor
must
maintain
tight
regul
innat
immun
respons
prevent
excess
inflamm
even
face
pathogen
infect
import
immun
respons
compromis
organ
function
lung
alveolar
macrophag
play
key
role
regul
balanc
activ
inhibitori
signal
immun
correspond
receptor
engag
alveolar
macrophag
balanc
determin
activ
threshold
describ
innat
immun
rheostat
similar
light
control
dimmer
switch
activ
molecul
alveolar
macrophag
includ
prr
molecul
involv
dampen
respons
includ
suppress
cytokin
eg
adenosin
balanc
activ
dampen
pathway
site
specif
mucos
site
balanc
tip
favour
dampen
pathway
prevent
excess
potenti
damag
immun
reaction
kinet
respiratori
infect
describ
three
stage
homeostasi
inflamm
resolut
homeostasi
lung
maintain
via
signal
epitheli
correspond
receptor
found
alveolar
macrophag
signal
serv
keep
macrophag
rel
inactiv
state
pathogen
encount
inflamm
stage
begin
inflamm
trigger
direct
damag
epithelium
infect
viru
epitheli
damag
also
lead
loss
dampen
ligand
found
epitheli
cell
express
eg
addit
upregul
macrophag
allow
helper
signal
provid
b
dc
cell
resolut
stage
macrophag
upregul
express
level
exceed
seen
infect
therefor
macrophag
stronger
dampen
state
higher
activ
threshold
suppress
tlr
respons
also
maintain
alveolar
macrophag
resolut
ideal
immunomodul
would
serv
benefici
stage
ill
target
cell
involv
immunopathogenesi
prevent
pathogen
clearanc
innat
adapt
immun
respons
must
also
allow
prevent
suscept
repeat
secondari
infect
conceptu
inflamm
stage
may
optim
stage
therapeut
intervent
stage
macrophag
apc
interact
cell
elicit
effector
immun
respons
number
costimulatori
molecul
necessari
develop
respons
includ
interact
apc
fusion
protein
ig
block
interact
administr
ig
mice
infect
influenza
found
significantli
decreas
morbid
lung
patholog
even
treatment
given
late
day
ig
treatment
affect
viral
titr
lung
treat
untreat
mice
show
similar
abil
clear
viru
inflamm
epitheli
cell
damag
lead
loss
epitheli
therebi
contribut
loss
dampen
signal
altern
therapeut
approach
would
therefor
treat
exogen
experi
mice
infect
influenza
treat
fc
time
infect
day
show
reduc
morbid
lung
inflamm
increas
recoveri
addit
agonist
monoclon
antibodi
show
similar
benefici
effect
fc
agonist
antibodi
treatment
affect
viral
clearanc
data
indic
agonist
promis
novel
therapeut
resolut
lung
inflamm
lead
excess
dampen
respons
increas
level
express
thu
lead
state
wherebi
lung
actual
suscept
secondari
infect
innat
immun
rheostat
appear
qualit
differ
influenza
infect
sustain
increas
basal
level
observ
alveolar
macrophag
mice
influenza
also
associ
appar
desensit
tlr
ligand
last
week
mice
challeng
tlr
agonist
week
influenza
infect
show
decreas
kc
express
alveolar
macrophag
epitheli
cell
compar
uninfect
control
effect
owe
differ
tlr
express
level
instead
reduc
level
nuclear
transloc
respons
tlr
ligat
alveolar
macrophag
studi
viru
strain
influenza
ahong
ha
na
gene
backbon
rsv
system
indic
sever
initi
infect
relat
increas
resolut
influenza
caus
express
rsv
infect
innat
imprint
account
observ
increas
suscept
secondari
bacteri
infect
follow
influenza
mice
infect
influenza
follow
streptococcu
bacteria
week
infect
show
increas
bacteri
load
lung
also
much
higher
mortal
mice
given
viru
bacteria
gould
j
godle
vekaria
hilti
r
snelgrov
b
askona
hussel
imperi
colleg
london
unpublish
observ
note
knockout
mice
control
respiratori
bacteri
infect
better
anim
summari
posit
innat
immun
rheostat
specif
person
bodi
site
previou
pathogen
experi
individu
begin
slightli
differ
recalibr
time
new
infect
experienc
concept
also
relev
asthma
complic
aris
chronic
lung
condit
hypersensit
autoimmun
respons
vaccin
exuber
inflammatori
respons
associ
virul
influenza
strain
compris
dysregul
cytokin
product
enhanc
recruit
innat
inflammatori
cell
lung
dr
jerri
aldridg
st
jude
children
research
hospit
memphi
tn
usa
describ
uniqu
subset
dendrit
cell
dc
contribut
lung
patholog
studi
evalu
alter
innat
cell
traffick
hypothesis
occur
sever
influenza
infect
mice
infect
lethal
subleth
viru
inoculum
greater
increas
subset
lung
dc
call
tipdc
occur
anim
infect
compar
similarli
tipdc
also
increas
lung
mice
lethal
infect
viru
compar
infect
strain
tipdc
found
recruit
lung
influenza
infect
chemokin
howev
mice
ablat
tipdc
recruit
reduct
morbid
protect
lethal
challeng
observ
addit
found
number
significantli
reduc
airway
mediastin
lymph
node
mice
lead
compromis
viral
clearanc
studi
use
viru
mutat
two
epitop
np
pa
viru
compar
replic
compet
tipdc
mice
infect
mutant
viru
adopt
transfer
mice
unabl
elicit
respons
contrast
tipdc
adopt
transfer
mice
abl
rescu
respons
therefor
antigen
like
present
tipdc
necessari
prerequisit
recruit
respons
lung
complet
deplet
tipdc
infect
lung
detriment
mous
surviv
therefor
partial
reduct
tipdc
recruit
undertaken
lessen
inflamm
retain
recruit
benefici
cell
initi
experi
use
vari
dose
neutralis
antibodi
mice
reduc
tipdc
recruit
via
ligand
neither
approach
effect
peroxisom
agonist
pioglitazon
alreadi
licens
drug
type
ii
diabet
multipl
pharmacolog
action
includ
reduc
monocyt
chemotact
ino
level
pioglitazon
mice
given
viru
reduc
morbid
mortal
significantli
without
affect
viral
replic
protect
found
correl
reduc
product
fewer
number
tipdc
lung
infect
fact
viral
replic
alter
pioglitazon
yet
mortal
improv
experi
suggest
mechan
viral
clearanc
might
oper
perhap
amount
damag
caus
cell
rate
injuri
repair
alter
cell
type
within
infiltr
inflammatori
popul
interestingli
earli
increas
lung
neutrophil
observ
mice
wherea
earlier
studi
correl
increas
neutrophil
number
wors
diseas
mice
anoth
action
pioglitazon
alter
mitochondri
membran
potenti
might
lead
intracellular
inflammatori
pathway
apoptosi
may
enhanc
inflamm
circumst
potenti
effect
explor
futur
experi
howev
pioglitazon
also
observ
enhanc
mitochondri
biogenesi
without
alter
membran
potenti
neuron
initi
studi
suggest
anoth
agonist
drug
rosiglitazon
may
offer
superior
effect
pioglitazon
mous
influenza
model
experi
current
ongo
address
whether
agonist
therapeut
effect
examin
effect
treatment
combin
antivir
drug
aggreg
result
indic
increas
number
tipdc
correl
posit
patholog
mortal
antigen
present
tipdc
lung
necessari
optim
respons
mice
modul
tipdc
traffick
agonist
protect
lethal
influenza
challeng
mice
drug
offer
possibl
therapeut
intervent
studi
sever
influenza
diseas
human
regard
epidemiolog
studi
popul
take
regular
treatment
assess
incid
sever
influenza
inflammatori
diseas
would
interest
terrenc
tumpey
us
cdc
present
data
experi
use
cytokin
knockout
mice
assess
effect
diseas
sever
individu
cytokin
cytokin
receptor
knockout
mice
receptor
tnf
receptor
use
viru
experi
test
whether
specif
cytokin
involv
caus
sever
diseas
surprisingli
result
show
absenc
effect
mous
morbid
mortal
viru
titr
challeng
highli
pathogen
ahong
viru
ahong
viru
highli
pathogen
mous
may
viru
exert
lethal
quickli
caus
system
infect
includ
enceph
effect
lung
patholog
may
mask
therefor
detect
subtl
differ
longer
time
frame
subsequ
experi
use
ahong
viru
lower
lethal
mice
infect
use
viru
show
knockout
mice
continu
show
differ
diseas
compar
mice
howev
knockout
mice
display
increas
morbid
mortal
delay
viral
clearanc
infect
strain
lesser
lethal
contrast
knockout
mous
exhibit
decreas
morbid
upon
ahong
ahong
viru
challeng
appear
relat
viru
spread
similar
viru
titr
found
lung
brain
lymphoid
organ
mice
howev
although
mice
exhibit
reduc
diseas
progress
mortal
rate
ultim
affect
mice
succumb
day
eleven
tripl
knockout
mice
defici
receptor
genotyp
bred
background
may
relev
model
pathogenesi
singl
cytokin
observ
dysregul
viru
infect
moreov
function
redund
cytokin
studi
effect
delet
one
cytokin
may
limit
valu
context
result
tripl
mutant
mice
challeng
ahong
viru
show
signific
decreas
kc
mous
equival
human
product
compar
infect
mice
correl
decreas
pulmonari
histopatholog
chang
decreas
morbid
signific
delay
time
death
compar
mice
howev
eventu
mice
eventu
succumb
infect
day
nine
therefor
lack
signal
ultim
protect
death
model
line
result
singl
mutant
mice
challeng
highli
pathogen
viru
reduc
morbid
seen
tripl
mutant
mice
associ
differ
lung
viral
titr
observ
suggest
antivir
drug
suboptim
reduc
viral
titr
might
produc
concurr
reduct
cytokin
associ
increas
lung
inflamm
morbid
howev
studi
antivir
drug
report
upon
model
earlier
studi
experiment
induc
human
influenza
find
reduct
proinflammatori
cytokin
administr
neuraminidas
inhibitor
dr
patrick
woo
univers
hong
kong
present
data
combin
antivir
immunomodul
treatment
mice
amongst
human
case
mortal
remain
high
despit
oseltamivir
use
mani
patient
although
delay
time
treatment
major
variabl
mani
case
patient
sever
diseas
suffer
viral
pneumonia
involv
typic
associ
hypercytokinaemia
earli
attempt
manag
excess
cytokin
respons
involv
administr
system
corticosteroid
howev
corticosteroid
treatment
associ
advers
side
effect
improv
surviv
sever
pandem
ill
network
inflammatori
mediat
cellular
signal
cascad
highli
complex
make
identif
appropri
therapeut
intervent
time
difficult
earlier
studi
show
knockout
mice
exhibit
lower
mortal
viru
infect
mice
improv
surviv
correl
lower
level
higher
level
interestingli
mice
exhibit
higher
lung
viral
load
day
viru
eventu
clear
level
seen
mice
day
prostaglandin
found
affect
cytokin
product
inflammatori
respons
dramat
limit
product
follow
observ
celecoxib
inhibitor
test
mous
model
viru
infect
without
antivir
zanamivir
given
intraperiton
addit
mesalazin
drug
wide
use
treat
inflammatori
bowel
diseas
gemfibrozil
fibrat
report
benefici
effect
murin
influenza
also
test
drug
also
inhibit
cyclooxygenas
pathway
activ
treatment
initi
hour
infect
signific
improv
surviv
rate
reduct
inflammatori
marker
much
less
histopatholog
chang
observ
group
treat
combin
therapi
zanamivir
celecoxib
mesalazin
compar
zanamivir
alon
viral
titr
similar
found
zanamivir
treatment
alon
although
sever
anim
tripl
regimen
group
protract
viral
detect
immunomodul
agent
use
alon
small
delay
death
thu
tripl
combin
therapi
zanamivir
celecoxib
mesalazin
significantli
decreas
mortal
correl
reduc
cytokin
level
cellular
infiltr
lung
import
extend
studi
model
system
consid
evalu
therapi
random
control
clinic
trial
human
sever
influenza
particularli
ill
approach
might
also
benefit
sever
system
inflammatori
reaction
caus
insult
dr
david
fedson
sergi
haut
franc
present
background
concept
use
gener
immunomodulatori
agent
treat
sever
influenza
number
inflammatori
condit
induc
differ
stimuli
share
common
inflammatori
respons
pathway
sepsi
sever
influenza
lead
develop
ard
mof
characteris
exuber
dysregul
cytokin
respons
influenza
associ
wors
outcom
peopl
cardiovascular
pulmonari
diseas
diabet
renal
diseas
obes
asthma
late
pregnanc
condit
associ
chronic
inflamm
statin
coenzym
reductas
inhibitor
act
reduc
cholesterol
commonli
prescrib
cardiovascular
indic
statin
also
exert
pleiotrop
immunomodulatori
effect
larg
retrospect
observ
studi
patient
hospitalis
acut
coronari
syndrom
ac
show
inpati
statin
reduc
hospit
mortal
compar
ac
patient
given
statin
retrospect
cohort
studi
hospitalis
patient
bacteri
sepsi
show
statin
appear
reduc
mortal
importantli
sever
observ
studi
shown
outpati
statin
treatment
associ
reduct
pneumonia
hospitalis
death
howev
observ
studi
shown
outpati
statin
offer
signific
protect
epidemiolog
studi
regardless
outcom
limit
includ
inadequ
sampl
size
misclassif
pneumonia
imprecis
ascertain
statin
use
confound
variabl
eg
sever
underli
condit
function
statu
potenti
interact
statin
medic
one
studi
abstract
report
result
retrospect
cohort
studi
usa
evalu
nearli
adult
hospitalis
season
influenza
patient
receiv
inpati
statin
treatment
rel
reduct
hospit
mortal
report
potenti
immunomodulatori
agent
consid
treat
sever
influenza
includ
agonist
fibrat
agonist
glitazon
fibrat
glitazon
immunomodulatori
properti
part
mediat
increas
activ
activ
downregul
ino
whilst
downregul
shown
benefici
effect
experi
influenza
mice
even
though
agent
known
antivir
activ
increas
influenza
viru
replic
report
thu
far
epidemiolog
data
effect
drug
patient
pneumonia
influenza
would
great
interest
adequ
power
randomis
control
trial
statin
immunomodulatori
agent
influenza
need
one
studi
organis
ard
clinic
trial
network
statin
trial
influenza
patient
stip
clinicaltrialsgov
identifi
anoth
intern
forum
acut
care
trialist
infact
howev
recruit
patient
pandem
delay
enrol
highlight
need
prepar
clinic
research
infrastructur
respond
new
pandem
viru
conduct
trial
immunomodulatori
treatment
sever
season
influenza
acut
respiratori
infect
dr
michael
tuvim
univers
texa
md
anderson
cancer
center
describ
data
illustr
induct
innat
immun
respons
airway
epitheli
cell
protect
influenza
infect
anim
model
previous
group
shown
aerosolis
h
influenza
bacteri
lysat
complet
protect
mice
lethal
challeng
streptococcu
pneumonia
administ
hour
beforehand
bacteri
lysat
administr
also
prevent
mortal
challeng
rang
bacteri
fungal
pathogen
lysat
administ
hour
challeng
influenza
viru
increas
mous
surviv
reduc
weight
loss
decreas
lung
viral
titr
protect
effect
lysat
therapi
depend
upon
time
administr
decreas
given
hour
day
influenza
challeng
studi
lysat
treatment
later
timepoint
need
assess
possibl
therapeut
valu
prophylaxi
intervent
would
probabl
need
taken
sustain
basi
mice
multipl
treatment
abl
induc
level
protect
observ
one
treatment
ie
repeat
treatment
caus
tachyphylaxi
protect
effect
site
specif
aerosolis
bacteri
lysat
protect
influenza
viru
administ
ip
iv
rout
unlik
kill
bacteri
lysat
administr
live
bacteria
day
influenza
challeng
promot
death
mice
day
later
mechan
protect
induc
lysat
treatment
bacteri
challeng
model
found
associ
depend
upon
recruit
leucocyt
predominantli
neutrophil
lung
mice
exhibit
enhanc
bacteri
kill
correl
increas
antimicrobi
peptid
bal
eg
lysozym
surfact
apoprotein
well
upregul
gene
express
nfkb
number
inflammatori
cytokin
includ
type
ii
ifn
howev
experi
use
knockout
mice
mab
cytokin
show
protect
independ
influenza
challeng
studi
protect
also
associ
although
proven
depend
upon
signific
rise
bronchial
lavag
level
lysat
administr
howev
influenza
challeng
lavag
cytokin
level
much
lower
compar
infect
mice
given
prior
lysat
treatment
serum
cytokin
slightli
rais
lysat
treatment
quickli
drop
hour
bacteri
lysat
rel
crude
mixtur
multipl
compon
use
knockout
mice
epitheli
resist
pathogen
found
requir
tlr
signal
compon
trif
part
cell
signal
pathway
compon
share
number
differ
tlr
type
elucid
tlr
involv
protect
function
bacteri
lysat
tlr
agonist
alon
combin
use
mice
synergist
combin
tlr
ligand
abl
recapitul
protect
effect
crude
bacteri
lysat
specif
combin
ligand
odn
synthet
ligand
respect
induc
protect
bacteri
influenza
viru
challeng
three
synthet
ligand
odn
test
conjunct
ligand
influenza
mous
model
show
compar
protect
surviv
rate
conclus
bacteri
lysat
administr
abl
induc
protect
influenza
epitheli
activ
tlr
agonist
deliv
topic
simul
effect
seen
crude
bacteri
lysat
inflamm
elicit
seen
larg
confin
lung
rather
system
care
safeti
studi
necessari
intervent
taken
human
studi
interest
test
combin
antivir
tlr
agonist
determin
effect
lysat
therapi
secondari
bacteri
infect
viral
infect
anim
dr
april
pilon
clarass
inc
usa
describ
role
mucos
protein
clara
cell
protein
respiratori
infect
produc
mani
tissu
bodi
highest
express
found
respiratori
tract
mainli
produc
clara
cell
epithelium
abund
singl
protein
normal
found
respiratori
mucosa
appear
multipl
function
act
clara
cell
facilit
cell
traffick
protein
transport
probabl
upon
cell
type
includ
vascular
epitheli
cell
neutrophil
lymphocyt
dendrit
cell
similar
manner
consensu
mechan
action
cell
type
appear
act
well
signal
epitheli
cell
defici
lead
sever
inflamm
airway
dysfunct
associ
diseas
pneumonia
ard
copd
asthma
pulmonari
fibrosi
maintain
airway
epithelia
overal
lung
function
autocrin
stimul
clara
cell
renew
preserv
pulmonari
structur
integr
suppress
signal
proinflammatori
cytokin
product
help
reduc
vascular
permeabl
well
acceler
viral
clearanc
possibl
interf
intracellular
viral
transport
one
audienc
member
describ
recent
work
found
inflamm
part
promot
downregul
abl
upregul
promot
stabilis
express
also
upregul
respiratori
tract
corticosteroid
recombin
complet
phase
iii
clinic
trial
infant
respiratori
distress
syndrom
rd
one
randomis
trial
neonat
found
singl
intratrach
administr
mgkg
safe
efficaci
significantli
decreas
pulmonari
inflamm
indic
short
term
total
protein
level
tracheal
aspir
show
decreas
day
treatment
indic
reduc
vascular
permeabl
reduc
number
infiltr
neutrophil
total
cell
count
also
seen
day
treatment
none
eleven
treat
infant
need
hospitalis
owe
respiratori
infect
compar
three
six
untreat
infant
mice
develop
increas
lung
epitheli
hypertrophi
greater
lung
cellular
infiltr
delay
viral
clearanc
compar
mice
vitro
rsv
infect
cell
line
also
show
addit
significantli
reduc
viral
titr
studi
assess
potenti
applic
differ
rout
administr
eg
topic
intraven
differ
influenza
strain
would
interest
cotton
rat
infect
influenza
viru
treat
intraperiton
demonstr
reduct
lung
viral
titr
furthermor
suppress
airway
constrict
inflamm
isol
rat
lung
perfus
bacteri
endotoxin
lp
rat
given
also
produc
less
pulmonari
rat
given
lp
alon
whether
might
prevent
secondari
bacteri
infect
warrant
studi
relev
anim
model
clinic
studi
topic
deliv
administ
warrant
develop
parenter
formul
would
interest
studi
patient
sever
ill
dr
andr
salazar
oncovir
inc
present
work
tlr
agonist
intervent
strategi
respiratori
pathogen
oncovir
develop
two
dsrna
therapeut
viral
mimic
agonist
synthet
dsrna
compos
acid
stabilis
carboxymethylcellulos
call
le
molecul
activ
epitheli
cell
myeloid
cell
initi
innat
immun
signal
cytokin
product
therebi
induc
antivir
state
found
induc
protect
rang
respiratori
mucos
pathogen
anim
model
includ
vaccinia
anthrax
herp
ebola
viru
mice
intranas
le
induc
protect
subsequ
viru
season
viru
infect
protect
correl
increas
express
cytokin
includ
well
increas
mrna
partial
protect
could
still
induc
le
administ
week
challeng
wherea
could
given
day
challeng
also
shown
protect
cotton
rat
model
influenza
treat
rat
demonstr
decreas
viral
titr
interestingli
histolog
show
treatment
caus
lung
inflamm
observ
control
phase
ii
clinic
trial
oncovir
inc
washington
dc
usa
intranas
dose
well
toler
seriou
side
effect
futur
plan
includ
test
appropri
anim
model
confirm
efficaci
follow
clinic
trial
confirm
safeti
assess
efficaci
use
vaccin
adjuv
intranas
live
attenu
vaccin
also
consider
nasal
deliv
le
may
offer
potenti
effect
prophylaxi
earli
treatment
influenza
respiratori
virus
dr
jame
larrick
stormbio
inc
new
jersey
usa
describ
compani
focu
treatment
immunolog
mediat
diseas
includ
influenza
treatment
aim
reduc
cytokin
storm
drug
current
develop
includ
superoxid
dismutas
mimet
antibodi
construct
block
interact
therapi
superoxid
dismutas
mimet
function
limit
express
ro
contribut
lung
immunopatholog
initi
anim
experi
compound
shown
modest
effect
howev
therefor
uncertain
whether
taken
forward
clinic
trial
studi
proprieti
antibodi
construct
pegyl
requir
increas
plasma
although
formul
also
reduc
cellular
bind
futur
work
may
includ
test
altern
antibodi
use
ig
fusion
protein
excess
product
associ
lung
injuri
neutralis
would
anticip
reduc
lung
damag
without
compromis
viral
clearanc
immun
cell
howev
observ
studi
clinic
data
report
date
regard
influenza
therapi
direct
experiment
data
need
relev
model
ali
one
point
regard
interven
acut
influenza
respons
may
initi
earli
infect
time
administr
may
difficult
get
right
clinic
trial
discuss
identifi
regulatori
development
issu
immunomodul
one
specif
question
would
could
immunomodul
approv
without
thorough
mode
action
mechanist
detail
instanc
pandem
influenza
emerg
infecti
diseas
streamlin
regulatori
approv
process
need
explor
perhap
similar
licensur
exist
pandem
influenza
vaccin
europ
emerg
use
authoris
eua
procedur
exist
unit
state
use
intraven
peramivir
treat
hospitalis
patient
pandem
ill
long
timelin
requir
obtain
drug
discoveri
market
patent
expir
time
may
discourag
smaller
compani
pursu
particular
molecul
may
possibl
reduc
regulatori
hurdl
novel
therapi
influenza
identifi
amongst
drug
alreadi
licens
treatment
diseas
establish
safeti
record
alreadi
exist
appli
sever
immunomodulatori
agent
propos
influenza
treatment
eg
inhibitor
statin
fibrat
glitazon
macrolid
mesalazin
howev
drug
identifi
pursu
way
littl
interest
larg
pharmaceut
compani
fund
must
sought
elsewher
normal
government
charit
fund
bodi
addit
therapeut
option
passiv
immunotherapi
via
convalesc
blood
product
immunoglobulin
ig
propos
treat
case
sever
influenza
convalesc
plasma
hyperimmun
sera
recent
studi
treatment
studi
patient
sever
pandem
ill
hong
kong
encourag
result
convalesc
blood
product
appear
benefici
pandem
passiv
immunotherapi
use
appar
success
individu
case
infect
clear
benefit
murin
model
diseas
intervent
may
serv
clear
viru
antibodi
also
act
immunomodulatori
factor
mechan
yet
fulli
elucid
rigor
control
clinic
trial
need
prove
benefici
effect
secondli
elucid
mechan
action
ifn
therapi
anoth
possibl
mean
treat
influenza
inde
earlier
observ
fatal
human
case
influenza
pneumonia
report
absenc
interferon
lung
tissu
recent
studi
patient
sever
pandem
ill
also
found
much
lower
plasma
level
compar
mild
ill
treatment
may
offer
advantag
tradit
approach
includ
avoid
gener
resist
mutat
novel
immunomodulatori
therapeut
proven
valu
influenza
ard
current
lack
although
grow
number
public
examin
impact
variou
immunomodul
experiment
system
mainli
mous
research
need
test
broader
array
novel
therapeut
extend
observ
relev
anim
model
understand
underli
mode
action
import
determin
take
account
differenti
host
respons
activ
differ
viru
strain
eg
versu
season
influenza
altern
option
would
also
target
host
cellular
interactom
viru
exampl
block
rafmekerk
kinas
pathway
may
also
reduc
diseas
knockout
mice
show
improv
surviv
upon
infect
season
influenza
summari
present
workshop
highlight
substanti
progress
made
understand
mechan
pulmonari
injuri
influenza
respiratori
viru
infect
complex
dynam
natur
event
play
inhibit
viral
replic
effici
antivir
like
essenti
suffici
achiev
optim
patient
outcom
sever
human
influenza
effect
immunomodulatori
intervent
particularli
combin
antivir
period
activ
viral
replic
need
patient
howev
function
redund
pathway
rapid
chang
respons
time
involv
creat
challeng
intervent
consider
heterogen
exist
innat
immun
respons
relat
host
viral
factor
key
question
regard
particular
target
intervent
appropri
level
inhibit
time
initi
cessat
intervent
within
cours
infect
appropri
patient
popul
remain
resolv
downregul
overli
exuber
innat
immun
respons
also
potenti
upregul
viral
replic
increas
risk
secondari
bacteri
infect
also
clear
defici
innat
immun
respons
exist
certain
situat
eg
inadequ
interferon
product
signal
might
amen
target
upregul
exogen
supplement
multipl
potenti
target
relat
interact
innat
immun
respons
underscor
challeng
decid
intervent
take
clinic
rigor
test
turn
uncertainti
emphasis
import
develop
anim
model
predict
diseas
pathogenesi
human
understand
limit
model
integr
find
differ
model
identifi
marker
surrog
might
predict
benefit
mani
present
workshop
address
studi
murin
model
especi
mous
strain
defin
genet
defect
extens
find
model
speci
key
point
studi
clinic
test
candid
agent
need
rigor
assess
clinic
virolog
immun
measur
part
safeti
issu
rais
modul
immun
respons
studi
select
immunomodul
uncompl
influenza
possibl
would
provid
use
inform
regard
possibl
effect
virolog
immun
respons
would
uncertain
valu
predict
safeti
efficaci
sever
diseas
state
like
influenza
viral
pneumonia
consequ
control
studi
particular
immunomodul
addit
antivir
therapi
hospitalis
patient
sever
ill
necessari
